Combined product, salt and use thereof
By developing a combination product of specific compounds and bile acid derivatives, acid-base addition salts are formed, and the poor effect and safety of existing hepatobiliary disease treatment methods are solved, significantly protecting hepatocytes and inhibiting T cell proliferation, providing Effective treatment options for PBC and PSC.
Patent Information
- Application Number
- PCT/CN2024/096519
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-17
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Existing treatment methods for hepatobiliary diseases such as PBC and PSC lack effective drugs, especially UDCA treatment is poor, OCA has safety problems, and PSC has no approved drugs, resulting in significant unsatisfactory treatment of hepatobiliary diseases.
Develop a combination product containing a specific compound or salt, solvate, hydrate or stereoisomer, in combination with bile acid or derivatives thereof, for the formation of acid-base addition salts for the treatment and prevention of liver disease and inflammation In sexual enteropathy, hepatocytes are significantly protected by specific compounds Y, N and their salt-type YN, reducing deoxycholic acid-induced damage, and inhibiting T cell proliferation.
It significantly improves the protective effect of hepatocytes, reduces the damage induced by deoxycholic acid, inhibits T cell proliferation, and provides a better treatment plan for hepatobiliary diseases, especially for PBC and PSC, which provides a safe and efficient treatment option.
Smart Images

Figure PCTCN2024096519-FTAPPB-I100001 
Figure PCTCN2024096519-FTAPPB-I100002 
Figure PCTCN2024096519-FTAPPB-I100003
Abstract
Description
A combination product, salt and use thereof Technical Field
[0001] The present invention belongs to the field of medicine and relates to a novel combination product, a pharmaceutical composition, a salt form and its use in treating and / or preventing diseases. Background Art
[0002] Liver disease is generally classified as acute or chronic based on the duration of the disease. Liver disease can be caused by infection, injury, exposure to drugs or toxic compounds, alcohol, impurities in food, abnormal accumulation of normal substances in the blood, autoimmune processes, genetic defects (such as hemochromatosis), or unknown causes. Liver disease is a leading cause of death worldwide.
[0003] Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are chronic, progressive cholestatic diseases with unknown pathological mechanisms that can ultimately lead to end-stage diseases such as cirrhosis, liver failure, and bile duct cancer (Galoosian, A., et al. (2020). "Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches." J Clin Transl Hepatol 8(1):49-60.). PBC is more common in women, accounting for up to 90% of the cases. It is an autoimmune disease in which the body's immune system harms the liver, primarily by damaging the small ducts in the liver, which can cause itching, fatigue, and metabolic problems. In the late stages, PBC can lead to cirrhosis (end-stage liver disease or stage IV scarring) and liver failure (Horwich, BHand H.Han (2021). Diagnosis and Treatment of Primary Biliary Cholangitis: A Patient-Friendly Summary of the 2018 AASLD Practice Guidance. 18(5): 255-259.). The incidence of PSC is much lower than that of PBC and is classified as a rare disease. 80% of patients have inflammatory bowel disease (Mago, S. and GYWu (2020). Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review. J Clin Transl Hepatol 8(3): 336-346.). As a chronic progressive disease with unknown pathogenesis, PSC damages both the intrahepatic and extrahepatic bile ducts, thereby inducing a series of gastrointestinal disease symptoms and increasing the incidence of bile duct cancer and colorectal cancer. In terms of treatment, the only drugs currently approved for PBC are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). The former has insufficient clinical patient response, while the latter has been issued a "black box warning" by the FDA due to dyslipidemia and pruritus. There are currently no approved drugs for the treatment of PSC.
[0004] Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid formed by the 7β-epimerization of chenodeoxycholic acid, a major bile acid. Its greater hydrophilicity makes it less toxic than cholic acid or chenodeoxycholic acid. The FDA first approved UDCA in 1987 for the dissolution of gallstones and the treatment of primary biliary cholangitis (PBC).
[0005] UDCA is currently the first-line drug for the treatment of PBC (Gulamhusein, AF and GM Hirschfield (2020). "Primary biliary cholangitis: pathogenesis and therapeutic opportunities." Nat Rev Gastroenterol Hepatol 17(2):93-110.), and has shown a remission effect in different preclinical animal models (Beuers, U., et al. (2015). "New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond." J Hepatol 62(1Suppl):S25-37.;Tang, N., et al. (2018). "The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats." Mol Med Rep 17(3):3837-3844.).
[0006] Obeticholic acid (OCA) is currently used as a second-line drug for the treatment of PBC. It has demonstrated significant therapeutic effects in mouse models of PBC, PSC, nonalcoholic steatohepatitis (NASH), and liver fibrosis (Gitto S., et al. (2018). “Guarneri V, Sartini A, et al. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives [J].” Expert Review of Gastroenterology & Hepatology, 2018, 12(2): 165-171.).
[0007] Norursodeoxycholic acid (NorUDCA) is a synthetic UDCA side-chain shortened homologue that is partially resistant to amidation and capable of bile-hepatic shunt. NorUDCA has been shown to have significant beneficial effects in experimental models of biliary injury (Fickert P., et al. (2018). “24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2(Abcb4) knockout mice.” Gastroenterology. 2006 Feb; 130(2): 465-81.). A Phase 2 clinical trial has been completed (NCT01755507).
[0008] UDCA is ineffective, with approximately 25%-50% of patients failing to respond (Lin-Xiiang Huang, et al. (2022). “Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.” Expert Review of Gastroenterology & Hepatology, 16:11-12, 1065-1078.). OCA, a second-line treatment, can cause safety issues such as pruritus and dyslipidemia; and there is currently no drug available for PSC. Both indications present significant unmet clinical needs. Because the liver is responsible for the body's primary function in drug metabolism, higher requirements are placed on drug safety when treating hepatobiliary diseases such as PBC or PSC. Therefore, there is an urgent need in this field for a new therapy for treating liver diseases such as PBC and PSC that is more effective and safer than existing therapies.
[0009] Summary of the Invention
[0010] The inventors of this application have solved the above-mentioned needs through creative work.
[0011] Specifically, the present invention relates to the following technical solutions:
[0012] In one embodiment, the present invention relates to a combination product comprising:
[0013] (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0014] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl;
[0015] or R 1 、R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0016] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0017] (b) bile acid or a derivative or analog thereof, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0018] In some preferred embodiments, the molar ratio of component (a) to component (b) is 1:1000-1000:1.
[0019] In another embodiment, the present invention relates to a pharmaceutical composition comprising:
[0020] (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0021] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 As defined herein;
[0022] (b) bile acid or its derivative or analogue or its pharmaceutically acceptable salt, solvate, hydrate or stereoisomer;
[0023] (c) pharmaceutically acceptable carriers, excipients and / or diluents.
[0024] In some preferred embodiments, the molar ratio of component (a) to component (b) is 1:1000-1000:1.
[0025] In yet another embodiment, the present invention relates to an acid-base addition salt of formula (II):
[0026] (A + ) m (B - ) n (C - ) p
[0027] (II)
[0028] in,
[0029] (a)A + is the cationic portion of the compound of formula (I);
[0030] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 As defined herein;
[0031] (b)B - is the anionic portion of a bile acid, a derivative thereof, or an analog thereof; and
[0032] (c)C - It is an acid anion;
[0033] wherein m, n and p are each independently an integer selected from 1-6 such that the salt configuration achieves charge balance, and when m=n, p is 0.
[0034] In yet another embodiment, the present invention relates to a combination product, a pharmaceutical composition, an acid-base addition salt, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments for use in treating, alleviating and / or preventing liver disease or inflammatory bowel disease.
[0035] In yet another embodiment, the present invention relates to a method for treating and / or preventing liver disease or inflammatory bowel disease, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0036] In yet another embodiment, the present invention relates to a kit comprising:
[0037] A combination product, an acid-base addition salt, a pharmaceutical composition, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof and instructions for use according to any one of the preceding embodiments,
[0038] The kit is used for treating and / or preventing liver disease or inflammatory bowel disease.
[0039] The details of the present application are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, illustrative methods and materials are now described. Other features, objects and advantages of the present application will be apparent from the specification and claims. In the specification and the appended claims, the singular also includes the plural, unless the context clearly provides otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present application belongs. All patents and publications cited in this specification are incorporated herein by reference in their entirety.
[0040] The contents of all references cited throughout this application (including literature references, issued patents, published patent applications, and co-pending patent applications) are hereby expressly incorporated herein by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1. Depicts the protective effects of Compound B, Compound Y, and Compound N on hepatocytes against deoxycholic acid (DCA)-induced cell injury. Compound B and Compound Y were administered at 100 μM, and Compound N was administered at 50 μM. Data are presented as mean ± SEM. ****P < 0.0001 vs. DCA, analyzed by one-way ANOVA in Graphpad Prism 8; ##P < 0.01, analyzed by unpaired t test in Graphpad Prism 8.
[0042] Figure 2. Describes the protective effects of Compound Y, Compound N, Compound Y + N, and YN salt on hepatocytes against deoxycholic acid (DCA)-induced cell damage. The YN salt concentration was 50 μM, which translates to a 50 μM Compound Y concentration, a 50 μM Compound N concentration, and a 50 μM + 50 μM Compound Y + N concentration. Data are presented as mean ± SEM. ****P < 0.0001, vs. DCA, analyzed by one-way ANOVA in Graphpad Prism 8. #### P < 0.0001, # P < 0.05, vs YN salt, analyzed by unpaired t test.
[0043] Figure 3 shows the protective effects of Compound Y, Compound N, and Compound Y + N on hepatocytes against deoxycholic acid (DCA)-induced cell damage. Compound Y was administered at a concentration of 100 μM, Compound N at a concentration of 50 μM, and Compound Y + N at a concentration of 100 μM + 50 μM. Data are presented as mean ± SEM. ****P < 0.0001, vs. DCA, analyzed by one-way ANOVA in Graphpad Prism 8.
[0044] Figure 4 shows the protective effects of compound combinations B + N and Y + N against deoxycholic acid (DCA)-induced cell injury in hepatocytes. Compound combination Y + N was administered at concentrations of 100 μM + 50 μM, and compound combination B + N was administered at concentrations of 100 μM + 50 μM. Data are presented as mean ± SEM. ****P < 0.0001 vs. DCA, analyzed by one-way ANOVA in Graphpad Prism 8; ###P < 0.001, analyzed by unpaired t test in Graphpad Prism 8.
[0045] Figure 5 shows the effects of Compound Y, Compound N, Compound combination Y + N, and Compound UDCA (U) on CD4-positive T cell proliferation. Compound Y concentration was 200 μM, Compound N concentration was 100 μM, Compound combination Y + N concentration was 200 μM + 100 μM, and Compound U concentration was 100 μM.
[0046] Figure 6 shows the effects of Compound Y, Compound N, Compound combination Y + N, and Compound UDCA (U) on CD8-positive T cell proliferation. Compound Y concentration was 200 μM, Compound N concentration was 100 μM, Compound combination Y + N concentration was 200 μM + 100 μM, and Compound U concentration was 100 μM.
[0047] Figure 7 shows the effects of different doses of Compound Y and Compound B on endpoint alkaline phosphatase (ALP) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). Compound Y doses were 100 mg / kg and 50 mg / kg, respectively; Compound B doses were 100 mg / kg and 50 mg / kg, respectively. Data are presented as mean ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, vs. ANIT, analyzed by one-way ANOVA in Graphpad Prism 8; #### p < 0.0001, analyzed by unpaired t-test in Graphpad Prism 8.
[0048] Figure 8 depicts the effects of different doses of Compound Y and Compound B on endpoint alanine aminotransferase (ALT) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). The doses of Compound Y were 100 mg / kg and 50 mg / kg, respectively; the doses of Compound B were 100 mg / kg and 50 mg / kg, respectively. Data are presented as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05, vs. ANIT, analyzed by one-way ANOVA in Graphpad Prism 8; ####p < 0.0001, ##p < 0.01, analyzed by unpaired t-test in Graphpad Prism 8.
[0049] Figure 9 shows the effects of different doses of Compound Y and Compound B on endpoint aspartyl transferase (AST) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). Compound Y doses were 100 mg / kg and 50 mg / kg, respectively; Compound B doses were 100 mg / kg and 50 mg / kg, respectively. Data are presented as mean ± SEM. **p < 0.01, *p < 0.05 vs. ANIT, analyzed by one-way ANOVA in Graphpad Prism 8; ##p < 0.01, analyzed by unpaired t-test in Graphpad Prism 8.
[0050] Figure 10. Depicts the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint serum alkaline phosphatase (ALP) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). For compound combination administration, the dose of B+U was 100 mg / kg (B) + 50 mg / kg (U), the dose of B+N was 100 mg / kg (B) + 50 mg / kg (N), the dose of Y+U was 100 mg / kg (Y) + 50 mg / kg (U), and the dose of Y+N was 100 mg / kg (Y) + 50 mg / kg (N). The dose of UDCA (U) as a positive control was 100 mg / kg. Data are presented as mean ± SEM. ****p < 0.0001, *p < 0.05 vs ANIT, analyzed by one-way ANOVA in Graphpad Prism 8. # P < 0.05, compound combination B + N vs. compound combination Y + N, analyzed by unpaired t test in Graphpad Prism 8.
[0051] Figure 11 shows the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint serum alanine aminotransferase (ALT) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). For compound combination administration, the doses of B+U were 100 mg / kg (B) + 50 mg / kg (U), the doses of B+N were 100 mg / kg (B) + 50 mg / kg (N), the doses of Y+U were 100 mg / kg (Y) + 50 mg / kg (U), and the doses of Y+N were 100 mg / kg (Y) + 50 mg / kg (N). The dose of UDCA (U) as a positive control was 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, *p<0.05, vs ANIT; ###p<0.001, ##p<0.01, vs U, analyzed by one-way ANOVA in Graphpad Prism 8.
[0052] Figure 12 shows the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint aspartate aminotransferase (AST) levels in mice orally administered with α-naphthyl isothiocyanate (ANIT). For compound combination administration, the doses for B+U were 100 mg / kg (B) + 50 mg / kg (U), the doses for B+N were 100 mg / kg (B) + 50 mg / kg (N), the doses for Y+U were 100 mg / kg (Y) + 50 mg / kg (U), and the doses for Y+N were 100 mg / kg (Y) + 50 mg / kg (N). The dose for UDCA (U) as a positive control was 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, *p<0.05, vs ANIT; ###p<0.001, ##p<0.01, vs U, analyzed by one-way ANOVA in Graphpad Prism 8.
[0053] Figure 13 shows the effects of Compound Y, Compound N, the compound combination Y + N, and the positive control UDCA (U) on serum alkaline phosphatase (ALP) levels in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). The high-dose Compound Y dose was 100 mg / kg, the Compound N dose was 56.5 mg / kg, and the Compound Y + N dose was 100 mg / kg (Y) + 56.5 mg / kg (N). The low-dose Compound Y concentration was 60 mg / kg, the Compound N concentration was 34 mg / kg, and the Compound Y + N dose was 60 mg / kg (Y) + 34 mg / kg (N). The UDCA dose was 100 mg / kg. Data are presented as mean ± SEM. ****P < 0.0001, ***P < 0.001, *P < 0.05, vs. DDC, analyzed by one-way ANOVA in Graphpad Prism 8; #### P < 0.0001, ## P < 0.01, vs. compound combination Y + N, analyzed by one-way ANOVA in Graphpad Prism 8.
[0054] Figure 14 shows the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint serum alkaline phosphatase (ALP) levels in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). When administered as a combination, each compound was administered at a dose of 100 mg / kg, and the positive control, UDCA (U), was administered at a concentration of 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, **p<0.01, *p<0.05 vs. DDC; #### p<0.0001 vs. U, analyzed by one-way ANOVA in Graphpad Prism 8.
[0055] Figure 15 shows the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint serum aspartate aminotransferase (AST) levels in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). When administered as a combination, each compound was administered at a dose of 100 mg / kg, and the positive control, UDCA (U), was administered at a concentration of 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, **p<0.01, *p<0.05 vs. DDC, analyzed by one-way ANOVA in Graphpad Prism 8.
[0056] Figure 16 shows the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on endpoint serum alanine aminotransferase (ALT) levels in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). When administered as a combination, each compound was administered at a dose of 100 mg / kg, and the positive control, UDCA (U), was administered at a concentration of 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, **p<0.01, *p<0.05 vs. DDC, analyzed by one-way ANOVA in Graphpad Prism 8.
[0057] Figure 17 depicts the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on the endpoint liver bile pigment deposit area in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). When the compound combinations were administered, each compound was administered at a dose of 100 mg / kg, and the positive control, UDCA (U), was administered at a concentration of 100 mg / kg. Data are presented as mean ± SEM. ****p<0.0001, ***p<0.001, **p<0.01, vs. DDC, analyzed by one-way ANOVA in Graphpad Prism 8.
[0058] Figure 18. Describes the effects of compound combinations (B+U, Y+U, B+N, Y+N) and the positive control UDCA (U) on the endpoint liver fibrosis area in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model). When administered in combination, each compound was administered at a dose of 100 mg / kg, and the UDCA (U) concentration used as the positive control was 100 mg / kg. Data are presented as mean ± SEM. ****p < 0.0001, **p < 0.01, *p < 0.05, vs. DDC, analyzed by one-way ANOVA in Graphpad Prism 8; # P < 0.05, vs. compound combination Y + N, analyzed by unpaired t test in Graphpad Prism 8.
[0059] Figure 19 shows the effects of compound combination Y + N on mouse body weight at the endpoint of a dextran sulfate sodium salt (DSS)-induced enteritis model. The doses of compound combination Y + N were 100 mg / kg + 56.5 mg / kg (Y:N molar ratio approximately 2:1). Data are presented as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05, vs. DSS, analyzed by one-way ANOVA in Graphpad Prism 8.
[0060] Figure 20 shows the effects of compound combination Y + N on the DAI score at the endpoint of a dextran sulfate sodium salt (DSS)-induced enteritis model in mice. The doses of compound combination Y + N were 100 mg / kg + 56.5 mg / kg (Y:N molar ratio approximately 2:1). Data are presented as mean ± SEM. ****p < 0.0001, *p < 0.05 vs. DSS, analyzed by one-way ANOVA in Graphpad Prism 8.
[0061] Figure 21 shows the effects of compound combination Y + N on colon length at the endpoint of a dextran sulfate sodium salt (DSS)-induced enteritis model in mice. The doses of compound combination Y + N were 100 mg / kg + 56.5 mg / kg (Y:N molar ratio approximately 2:1). Data are presented as mean ± SEM. ****p < 0.0001, **p < 0.01, vs. DSS, analyzed by one-way ANOVA in Graphpad Prism 8. DETAILED DESCRIPTION
[0062] definition
[0063] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are those widely used in the respective fields and are standard procedures. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0064] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0065] As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, and most preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo.
[0066] As used herein, the term "alkoxy" refers to -O-(alkyl) and -O-(cycloalkyl), wherein alkyl or cycloalkyl are as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0067] As used herein, the terms "halo" and "halogen" refer to fluoro, chloro, bromo, and iodo.
[0068] As used herein, the term "haloalkyl" by itself or as part of another substituent refers to an alkyl group in which some or all of the hydrogen atoms are replaced by halogen atoms. For alkyl, haloalkyl can have any suitable number of carbon atoms, such as C1-6. For example, haloalkyl includes trifluoromethyl, fluoromethyl, etc. In some cases, the term "perfluoro" can be used to define a compound or group in which all hydrogen atoms are replaced by fluorine. For example, perfluoromethyl refers to 1,1,1-trifluoromethyl.
[0069] As used herein, the term "hydroxy" refers to an -OH moiety.
[0070] The present invention also includes various deuterated forms of formula (I). Each available hydrogen atom connected to the carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of formula (I) with reference to relevant literature. When preparing the deuterated form of formula (I), commercially available deuterated starting materials can be used, or they can use conventional techniques to adopt deuterated reagents to synthesize, and the limiting examples of deuterated reagents include: deuterated borane, trideuteroborane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated iodoethane and deuterated iodomethane etc.
[0071] "Pharmaceutically acceptable" means that the ingredients in question are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0072] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound when used herein. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, hydrochloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). A pharmaceutically acceptable salt may involve the inclusion of another molecule, such as acetate ion, succinate ion, or other counterion. Counterion can be any organic or inorganic module that stabilizes the charge of the parent compound. In addition, a pharmaceutically acceptable salt may have more than one charged atom in its structure. In the case where multiple charged atoms are part of a pharmaceutically acceptable salt, multiple counterions may be present. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.
[0073] As used herein, the term "acid anion" refers to an anion produced when an acid ionizes. Common acid anions include chloride, bromide, iodide, carbonate, bicarbonate, sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, formate, acetate, and the like. The acid anion may be -1, -2, -3, -4, and the like.
[0074] As used herein, the term "pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, formulation adjuvant, or carrier conventional in the art used with a therapeutic agent, which together constitutes a "pharmaceutical composition" for administration to an individual. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration employed and is compatible with the other ingredients of the formulation. A pharmaceutically acceptable carrier is suitable for the formulation employed.
[0075] As used herein, the term "pharmaceutically acceptable excipient" refers to a substance that facilitates administration of an active agent to an individual. Useful pharmaceutical excipients include, but are not limited to, binders, fillers, disintegrants, lubricants, glidants, coating agents, sweeteners, flavorings, and coloring agents.
[0076] Depending on the position and properties of the various substituents desired, the compounds of the present invention may contain one or more asymmetric centers. Asymmetric carbon atoms may exist in (R)- and / or (S)- configurations, resulting in racemic mixtures in the case of a single asymmetric center and in the case of multiple asymmetric centers, resulting in diastereomeric mixtures. In some cases, asymmetry may also exist due to hindered rotation around a specific bond, such as two substituted aromatic rings of a specific compound connected by the central bond. The substituents on the ring may also exist in cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers) are included within the scope of the present invention. Preferred compounds are those that produce more desired biological activity. Separated, pure or partially purified isomers and stereoisomers, or racemic mixtures or diastereomeric mixtures of the compounds of the present invention are included within the scope of the present invention. The purification and separation of such substances can be achieved by standard techniques known in the art.
[0077] Tautomers, sometimes called proton-shift tautomers, are two or more compounds related by the migration of a hydrogen atom accompanied by a switch of one or more single bonds and one or more adjacent double bonds. The compounds of the present invention may exist in one or more tautomeric forms.
[0078] The present invention also includes all suitable isotopic variations of the compounds of the present invention. An isotopic variation of a compound of the present invention is defined as a compound of the present invention in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium), 3 H (tritium), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 P. 33 P. 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 129 I and 131 I. Certain isotopic variations of the compounds of the present invention, for example, wherein one or more radioactive isotopes (e.g., 3 H or 14C) can be used for drug and / or substrate tissue distribution studies. Tritium and carbon-14 (i.e., 14 C) isotopes, due to their ease of preparation and detectability. Further, substitution with isotopes such as deuterium can provide definite therapeutic advantages resulting from better metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some cases. Isotopic variants of the compounds of the invention can generally be prepared using conventional methods known to those skilled in the art, for example, using the illustrative methods or the preparation methods described in the Examples below, using suitable isotopic variants of suitable reagents.
[0079] The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers or any mixture of said stereoisomers in any ratio. The separation of single stereoisomers, such as single enantiomers or single diastereomers, of the compounds of the present invention can be achieved by any suitable prior art method, such as chromatography, in particular, such as chiral chromatography.
[0080] The present invention includes all possible tautomers of the compounds of the present invention, either as single tautomers or as any mixture of said tautomers in any ratio.
[0081] As used herein, the term "solvate" or "solvate" refers to a compound of the present invention that forms a pharmaceutically acceptable solvate with one or more solvent molecules, non-limiting examples of which include water, ethanol, acetonitrile, isopropanol, DMSO, ethyl acetate, etc. Hydrates are a specific form of solvate in which the solvent is water.
[0082] As used herein, the terms "effective amount" and "therapeutically effective amount" refer to the dosage of a compound, such as a compound of the invention, a combination of compounds, or a salt form, that produces the therapeutic effect for which it is administered. The exact dosage will depend on the purpose of the treatment and will be determined by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition, 2006, Brunton, Ed., McGraw-Hill; and Remington: The Science and Practice of Pharmacy, 21st Edition, 2005, Hendrickson, Ed., Lippincott, Williams & Wilkins).
[0083] As used herein, " treatment (treatment or treating) " is the method for obtaining beneficial or desired result (including clinical outcome).For the purpose of the application, beneficial or desired clinical outcome includes but is not limited to one or more of the following: alleviate one or more symptoms caused by the disease, reduce the degree of the disease, stabilize the disease (for example, prevent or delay the deterioration of the disease), prevent or delay the spread of the disease (for example, metastasis), prevent or delay the recurrence of the disease, delay or slow down the progress of the disease, improve the disease state, provide the alleviation (partial or complete) of the disease, reduce the dosage of one or more other drugs required for the treatment of the disease, delay the progress of the disease, increase or improve the quality of life, increase weight gain and / or prolong survival." treatment " also encompasses the pathological consequences (such as, tumor volume) that reduce cancer. The method of the application contemplates any one or more of these treatment aspects.
[0084] As used herein, "prevention" or "preventing" includes providing protection against the occurrence or recurrence of a disease in an individual who may be susceptible to the disease but has not yet been diagnosed with the disease.
[0085] The terms "subject," "individual," and "patient" are used interchangeably herein to refer to mammals, including but not limited to humans, cows, horses, cats, dogs, rodents, or primates. In some embodiments, the individual is a human.
[0086] An "effective amount" of an agent is an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive result. The specific dosage may vary depending on one or more of the following: the particular agent selected, the dosing regimen to be followed, whether it is administered in combination with other compounds, the timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.
[0087] As used herein, the term "synergistic" or "synergistic" is used to refer to the result of the combination of two compounds, components, or targeting agents being greater than the sum of the individual agents together. The term "synergistic" or "synergistic" means that the disease condition or condition being treated is improved compared to when each compound, component, or targeting agent is used alone. This improvement in the disease condition or condition being treated is a "synergistic effect." A "synergistic amount" is the amount of a combination of two compounds, components, or targeting agents that results in a synergistic effect ("synergistic" as defined herein).
[0088] Determining the synergistic interaction between one or both components, the optimal range of the effect, and the absolute dose range of each component for the effect can be clearly measured by administering the components within different w / w ratios and dosages to patients in need of treatment. However, observing synergy in in vitro or in vivo models can predict the effect in humans and other species, as well as existing in vitro or in vivo models as described herein to measure synergistic effects, and the results of such studies can also be used to predict the desired effective dose and plasma concentration ratio range in humans and other species, as well as absolute doses and plasma concentrations, by applying pharmacokinetic / pharmacodynamic methods.
[0089] It should be understood that embodiments of the application described herein include "consisting of" and / or "consisting essentially of.
[0090] Reference herein to "about" a value or parameter includes (and describes) variations with respect to that value or parameter itself. For example, description referring to "about X" includes description of "X."
[0091] As used herein, the term "about XY" has the same meaning as "about X to about Y."
[0092] As used herein, the term "about" when used to modify an amount of an ingredient or reactant of the invention refers to variations in the numerical amount that may occur, for example, in typical measurements and liquid handling procedures used to prepare concentrates or actual use solutions; accidental errors in such procedures; differences in the manufacture, source, or purity of ingredients used to prepare the compositions or practice the methods; etc. The term "about" also includes amounts that vary due to different equilibrium conditions relative to the composition obtained from a particular starting mixture. Whether or not modified by the term "about," the claims include equivalent amounts of the amounts. In one embodiment, the term "about" means within 10% of the reported value, preferably within 5% of the reported value.
[0093] Those skilled in the art will understand that when a numerical value is stated in a claim, whether or not it is preceded by "about," the actual value of the numerical value may fluctuate by 10% (±10%) above or below the stated value, preferably by 5% (±5%) above or below the stated value.
[0094] As used herein and in the appended claims, the singular forms "a," "an," "or," and "the" include plural referents unless the context clearly dictates otherwise.
[0095] Implementation Plan Description
[0096] Combination products
[0097] In some aspects, the present disclosure provides a combination product comprising:
[0098] (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0099] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl;
[0100] or R 1 、R 2 and R 3Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0101] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0102] (b) bile acid or a derivative or analog thereof, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0103] In a further embodiment, the molar ratio of component (a) to component (b) is 1:1000-1000:1.
[0104] In a further embodiment, R 1 、R 2 and R 3 are independently selected from hydrogen, hydroxy, methoxy and benzyloxy, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1 ... 1 、R 2 and R 3 One or both of them are hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 1 、R 2 and R 3 One of them is hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0105] In a further embodiment, R 4 、R 5 and R 6 are independently selected from hydrogen, hydroxy and methoxy, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1 ...4 、R 5 and R 6 One or both of them are hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 4 、R 5 and R 6 One of them is hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0106] In further embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate. Preferably, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate or hydrochloride. More preferably, the pharmaceutically acceptable salt of the compound of formula (I) is hydrochloride.
[0107] In a further embodiment, the compound of formula (I) is selected from:
[0108] In a further embodiment, the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid and tauroursodeoxycholic acid, etc.
[0109] In a further embodiment, the molar ratio of component (a) to component (b) is 1:100-100:1. Preferably, the molar ratio of component (a) to component (b) is 1:90-90:1, 1:80-80:1, 1:70-70:1, 1:60-60:1, 1:50-50:1, 1:40-40:1, 1:30-30:1, 1:20-20:1 or 1:10-10:1. More preferably, the molar ratio of component (a) to component (b) is 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1 or any value therebetween. In some embodiments, the molar ratio of component (a) to component (b) is 1:5-5:1, preferably 1:2-2:1, and more preferably 1:1-2:1. In some embodiments, the molar ratio of component (a) to component (b) is 1:1 or 2:1.
[0110] In a further embodiment, the combination product is used to treat and / or prevent liver disease or inflammatory bowel disease, preferably chronic cholestatic liver disease. Preferably, the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (especially progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (especially hepatocellular carcinoma) and bile duct cancer. More preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by inflammatory bowel disease. Preferably, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0111] In a further embodiment, the component (a) and the component (b) have a synergistic effect in alleviating deoxycholic acid-induced hepatocellular damage.
[0112] Pharmaceutical composition
[0113] In some aspects, the present disclosure provides a pharmaceutical composition comprising:
[0114] (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0115] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl;
[0116] or R 1 、R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0117] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0118] (b) bile acid or its derivative or analogue or its pharmaceutically acceptable salt, solvate, hydrate or stereoisomer;
[0119] (c) pharmaceutically acceptable carriers, excipients and / or diluents.
[0120] In a further embodiment, the molar ratio of component (a) to component (b) is 1:1000-1000:1.
[0121] In a further embodiment, R 1 、R 2 and R 3 are independently selected from hydrogen, hydroxy, methoxy and benzyloxy, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1 ... 1 、R 2 and R 3 One or both of them are hydrogen, or R 1 、R 2 and R 3Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 1 、R 2 and R 3 One of them is hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0122] In a further embodiment, R 4 、R 5 and R 6 are independently selected from hydrogen, hydroxy and methoxy, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1 ... 4 、R 5 and R 6 One or both of them are hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 4 、R 5 and R 6 One of them is hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0123] In further embodiments, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate. Preferably, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate or hydrochloride. More preferably, the pharmaceutically acceptable salt of the compound of formula (I) is hydrochloride.
[0124] In a further embodiment, the compound of formula (I) is selected from:
[0125] In a further embodiment, the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid and tauroursodeoxycholic acid, etc.
[0126] In a further embodiment, the molar ratio of component (a) to component (b) is 1:100-100:1. Preferably, the molar ratio of component (a) to component (b) is 1:90-90:1, 1:80-80:1, 1:70-70:1, 1:60-60:1, 1:50-50:1, 1:40-40:1, 1:30-30:1, 1:20-20:1 or 1:10-10:1. More preferably, the molar ratio of component (a) to component (b) is 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1 or any value therebetween. In some embodiments, the molar ratio of component (a) to component (b) is 1:5-5:1, preferably 1:2-2:1, and more preferably 1:1-2:1. In some embodiments, the molar ratio of component (a) to component (b) is 1:1 or 2:1.
[0127] In a further embodiment, the pharmaceutical composition is used to treat and / or prevent liver disease or inflammatory bowel disease, preferably chronic cholestatic liver disease. Preferably, the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer. More preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by inflammatory bowel disease. Preferably, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0128] In a further embodiment, the component (a) and the component (b) have a synergistic effect in alleviating deoxycholic acid-induced hepatocellular damage.
[0129] Acid-base addition salts
[0130] In some aspects, the present disclosure provides an acid-base addition salt of formula (II):
[0131] (A + ) m (B - ) n (C - ) p
[0132] (II)
[0133] in,
[0134] (a)A + is the cationic portion of the compound of formula (I);
[0135] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl,
[0136] or R 1 、R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N,
[0137] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;
[0138] (b)B - is the anionic portion of a bile acid, a derivative thereof, or an analog thereof; and
[0139] (c)C - It is an acid anion;
[0140] wherein m, n and p are each independently an integer selected from 1-6 such that the salt configuration achieves charge balance, and when m=n, p is 0.
[0141] In a further embodiment, R 1 、R 2 and R 3 are independently selected from hydrogen, hydroxy, methoxy and benzyloxy, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1 ... 1 、R 2 and R 3 One or both of them are hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 1 、R 2 and R 3 One of them is hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0142] In a further embodiment, R 4 、R 5 and R 6 are independently selected from hydrogen, hydroxy and methoxy, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1 ... 4 、R 5 and R 6 One or both of them are hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 4 、R 5 and R 6 One of them is hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0143] In a further embodiment, the cationic portion of the compound of formula (I) is selected from the group consisting of:
[0144] In a further embodiment, component (b) is an anionic moiety selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid, and tauroursodeoxycholic acid, and the like.
[0145] In a further embodiment, C - is a monovalent, divalent, trivalent, tetravalent acid anion or a mixture thereof. - is a monovalent, divalent or trivalent acid anion or a mixture thereof. More preferably, C - is a monovalent or divalent acid anion or a mixture thereof. Most preferably, C - It is a monovalent acid anion or a mixture thereof.
[0146] In further embodiments, m is 1, n is 1, and p is 0, or m is 2, n is 1, and p is 1.
[0147] In a further embodiment, the pharmaceutical composition is used to treat and / or prevent liver disease or inflammatory bowel disease, preferably chronic cholestatic liver disease. Preferably, the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer. More preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by inflammatory bowel disease. Preferably, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0148] Treatment and / or prevention
[0149] In some aspects, the present disclosure provides a method for treating and / or preventing liver disease. In some aspects, the method for treating and / or preventing liver disease comprises administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof according to any one of the preceding embodiments.
[0150] In some aspects, the present disclosure provides a method for treating and / or preventing cholestatic liver disease, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0151] In some aspects, the present disclosure provides a method for treating and / or preventing primary sclerosing cholangitis (PSC), comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof according to any one of the preceding embodiments. In some embodiments, the primary sclerosing cholangitis (PSC) is accompanied by the complication inflammatory bowel disease.
[0152] In some aspects, the present disclosure provides a method for treating and / or preventing primary biliary cirrhosis (PBC), comprising administering to a patient in need thereof a combination product, a pharmaceutical composition, an acid-base addition salt, or a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof according to any one of the foregoing embodiments. In some embodiments, the primary biliary cirrhosis (PBC) is associated with the complication inflammatory bowel disease.
[0153] In some aspects, the present disclosure provides a method for treating and / or preventing progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2, and 3), comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
[0154] In some aspects, the present disclosure provides a method of treating and / or preventing cystic fibrosis, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt according to any one of the preceding embodiments, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0155] In some aspects, the present disclosure provides a method for treating and / or preventing cholestatic liver disease, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0156] In some aspects, the present disclosure provides a method for treating and / or preventing drug-induced cholestasis or non-cholestatic liver disease, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt according to any one of the preceding embodiments, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0157] In some aspects, the present disclosure provides a method for treating and / or preventing chronic viral hepatitis (B, C, D), comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0158] In some aspects, the present disclosure provides a method for treating and / or preventing alcoholic or non-alcoholic steatohepatitis, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt according to any one of the preceding embodiments, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0159] In some aspects, the present disclosure provides a method of treating and / or preventing autoimmune hepatitis, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0160] In some aspects, the present disclosure provides a method of treating and / or preventing hemochromatosis, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt according to any one of the preceding embodiments, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0161] In some aspects, the present disclosure provides a method for treating and / or preventing Wilson's disease, alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) or bile duct cancer, comprising administering to a patient in need thereof a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of the preceding embodiments.
[0162] In some aspects, the present disclosure provides a method for treating and / or preventing inflammatory bowel disease, comprising administering to a patient in need thereof a combination product, a pharmaceutical composition, an acid-base addition salt, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof according to any one of the preceding embodiments. Preferably, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0163] In some aspects, the present disclosure provides a method of treating and / or preventing liver disease or inflammatory bowel disease, comprising:
[0164] Protocol 1, administering to a patient in need thereof:
[0165] (a) a therapeutically and / or prophylactically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0166] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl,
[0167] or R 1 、R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N,
[0168] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; or
[0169] Option 2, administering simultaneously, concurrently, separately or sequentially to a patient in need thereof:
[0170] (a) a therapeutically and / or prophylactically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof:
[0171] where R 1 、R 2 、R 3 、R 4 、R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl,
[0172] or R 1 、R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N,
[0173] or R 4 、R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; and
[0174] (b) a therapeutically and / or prophylactically effective amount of bile acid, a derivative or an analog thereof, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
[0175] In a further embodiment, R 1 、R 2 and R 3 are independently selected from hydrogen, hydroxy, methoxy and benzyloxy, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1 ... 1 、R 2 and R 3 One or both of them are hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R1 、R 2 and R 3 One of them is hydrogen, or R 1 、R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0176] In a further embodiment, R 4 、R 5 and R 6 are independently selected from hydrogen, hydroxy and methoxy, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1 ... 4 、R 5 and R 6 One or both of them are hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the R-1-2-1-2-1-1-1-1 and the carbon atoms to which they are attached together form a 5-membered heterocyclic ring containing one or more oxygen atoms. In yet a further embodiment, R 4 、R 5 and R 6 One of them is hydrogen, or R 4 、R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing two oxygen atoms.
[0177] In a further embodiment, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate. Preferably, the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate or hydrochloride. More preferably, the pharmaceutically acceptable salt of the compound of formula (I) is hydrochloride.
[0178] In a further embodiment, the compound of formula (I) is selected from:
[0179] In a further embodiment, the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid and tauroursodeoxycholic acid, etc.
[0180] In a further embodiment, the molar ratio of component (a) to component (b) is 1:1000-1000: 1. In a further embodiment, the molar ratio of component (a) to component (b) is 1:100-100: 1. Preferably, the molar ratio of component (a) to component (b) is 1:90-90: 1, 1:80-80: 1, 1:70-70: 1, 1:60-60: 1, 1:50-50: 1, 1:40-40: 1, 1:30-30: 1, 1:20-20: 1 or 1:10-10: 1. More preferably, the molar ratio of component (a) to component (b) is 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1 or any value therebetween. In some embodiments, the molar ratio of component (a) to component (b) is 1:5 to 5:1; preferably 1:2 to 2:1; more preferably 1:1 to 2:1. In some embodiments, the molar ratio of component (a) to component (b) is 1:1 or 2:1.
[0181] In a further embodiment, the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer. Preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by the complication inflammatory bowel disease.
[0182] In some embodiments, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0183] In a further embodiment, the component (a) and the component (b) have a synergistic effect in alleviating deoxycholic acid-induced hepatocellular damage.
[0184] In some aspects, the present disclosure provides a combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any of the preceding embodiments for use in treating, alleviating and / or preventing liver disease or inflammatory bowel disease.
[0185] In a further embodiment, the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer. Preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by the complication inflammatory bowel disease.
[0186] In some embodiments, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0187] Administration
[0188] Administration of the compounds or salt forms of the combinations of the present invention may be effected by any method capable of delivering the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical and rectal administration.
[0189] The compound or salt form of the method or combination of the present invention can be formulated before administration. Preferably, the formulation will be suitable for a specific mode of administration. These compounds can be formulated together with pharmaceutically acceptable carriers known in the art and administered in a variety of dosage forms known in the art. When preparing the pharmaceutical composition of the present invention, the active ingredient is usually mixed with a pharmaceutically acceptable carrier, or diluted with a carrier or encapsulated in a carrier. Such carriers include, but are not limited to, solid diluents or fillers, excipients, sterile aqueous media, and various non-toxic organic solvents. Dosage unit forms or pharmaceutical compositions include tablets, capsules such as gelatin capsules, pills, powders, granules, aqueous and non-aqueous oral solutions and suspensions, lozenges, troches, hard candies, sprays, creams, ointments, suppositories, pectins, gels, pastes, lotions, ointments, injections, elixirs, syrups, and parenteral solutions packaged in containers suitable for subdividing into individual doses.
[0190] Parenteral formulations include pharmaceutically acceptable aqueous or non-aqueous solutions, dispersions, suspensions, emulsions and sterile powders (for their preparation). Examples of carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils and injectable organic esters, such as ethyl oleate. Flowability can be maintained by using a coating such as lecithin, a surfactant or maintaining an appropriate particle size. Exemplary parenteral administration forms include solutions or suspensions of the compounds of the present invention in sterile aqueous solutions, such as propylene glycol aqueous solutions or dextrose solutions. If necessary, such dosage forms can be appropriately buffered.
[0191] In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc can be generally used for tableting purposes. Similar types of solid compositions can also be used in soft and hard filled gelatin capsules. Therefore, preferred materials include lactose (lactose or milk sugar) and high molecular weight polyethylene glycol. When aqueous suspensions or elixirs are needed for oral administration, the active compound therein can be combined with various sweeteners or flavorings, coloring agents or dyes, and if necessary, emulsifiers or suspending agents, and diluents such as water, ethanol, propylene glycol, glycerol or a combination thereof.
[0192] Methods of preparing various pharmaceutical compositions using specific amounts of active compounds are known or apparent to those skilled in the art. For example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th edition (1975).
[0193] Reagent test kit
[0194] In some aspects, the present disclosure provides a kit for treating and / or preventing liver disease or inflammatory bowel disease, comprising a combination product according to any one of the preceding embodiments, an acid-base addition salt, a pharmaceutical composition, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof and instructions for administering the therapeutic agent. In one embodiment, the instructions for use detail and define the mode of administration of the therapeutic agent, for example, for simultaneous, joint, separate or sequential administration of the therapeutic agent of the present invention. In one embodiment, the instructions for use detail and define the mode of administration of the therapeutic agent, for example, by specifying the number of days for administration of each therapeutic agent during a specific period of time to detail and define the mode of administration of the therapeutic agent.
[0195] In some aspects, the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer. Preferably, the liver disease is primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC). More preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by the complication inflammatory bowel disease.
[0196] In some aspects, the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
[0197] Example
[0198] The present invention is further described in detail below by way of examples, which should not be construed as limiting the present invention.
[0199] Materials and Reagents: Unless otherwise specified, all reagents used in the experimental sections of this invention were commercially available. For example, berberine hydrochloride (Compound B) and ursodeoxycholic acid (Compound U) were purchased from Energy Chemical. 10-week-old male C57BL / 6 mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd.
[0200] In obtaining the compounds and corresponding analytical data described in the Examples below, the following experimental and analytical protocols were followed unless otherwise indicated.
[0201] LC-MS: Unless otherwise noted, the analytical LC-MS system used consisted of a Shimadzu LCMS-2020 electrospray ionization (ESI) system in positive ion detection mode, equipped with a 20ADXR pump, a SIL-20ACXR autosampler, a CTO-20AC column oven, an M20APDA detector, and an LCMS2020MS detector. The column was a HALO C18 30 mm × 5.0 mm, 2.7 μm column. Mobile phase A was water containing 0.05% TFA, and mobile phase B was acetonitrile containing 0.05% TFA. The gradient was as follows: 5% mobile phase B to 100% (95%) over 2.0 minutes, held for 0.7 minutes, then returned to 5% mobile phase B over 0.05 minutes and held for 0.25 minutes. The column oven (CTO-20AC) was operated at 40.0°C. The flow rate was 1.5 mL / min, and the injection volume was 1 μL. The PDA (SPD-M20A) detection range was 190 nm to 400 nm. The MS detector was configured with electrospray ionization as the ionizable source; acquisition mode: scan; nebulizing gas flow rate: 1.5 L / min; drying gas flow rate: 15 L / min; detector voltage: tuning voltage ± 0.2 kV; DL temperature: 250°C; heating block temperature: 250°C; scan range: 90.00 m / z to 900.00 m / z. ELSD (Alltech 3300) detector parameters: drift tube temperature: 60 ± 5°C; N2 flow rate: 1.8 ± 0.2 L / min. The mobile phase gradient was optimized for each compound. The calculated masses correspond to the exact masses.
[0202] Preparative HPLC: Unless otherwise stated, preparative HPLC purifications were performed using a Waters Auto purification system (2545-2767) with a 2489 UV detector. The column was selected from one of the following: Waters C18, 19 mm × 150 mm, 5 μm; XBridge Prep OBD C18 column, 30 mm × 150 mm, 5 μm; XSelect CSH Prep C18 OBD column, 5 μm, 19 mm × 150 mm; XBridge Shield RP18 OBD column, 30 mm × 150 mm, 5 μm; Xselect CSH Fluorophenyl, 30 mm × 150 mm, 5 μm; or YMC-Actus Triart C18, 30 mm × 150 mm, 5 μm. The mobile phase consisted of a mixture of acetonitrile (5%-95%) in water containing 0.1% FA or 10 mmol / L NH4HCO3. The flow rate was maintained at 25 mL / min, the injection volume was 1200 μL, and the UV detector used two channels, 254 nm and 220 nm.The mobile phase gradient was optimized for each compound.
[0203] Chiral chromatography: Chiral analytical chromatography was performed on one of the following: Chiralpak AS, AD, Chiralcel OD, OJ, Chiralpak IA, IB, IC, ID, IE, IF, IG, IH columns (Daicel Chemical Industries, Ltd.), (R,R)-Whelk-O1, (S,S)-Whelk-O1 columns (Regis technologies, Inc.), CHIRAL Cellulose-SB, SC, SA columns (YMC Co., Ltd.); different column dimensions (50 mm × 4.6 mm, 100 mm × 4.6 mm, 150 mm × 4.6 mm, 250 mm × 4.6 mm, 50 mm × 3.0 mm, 100 mm × 3.0 mm), percentage of ethanol in hexane (% Et / Hex) or percentage of isopropanol in hexane (% IPA / Hex) as an isocratic solvent system, or using supercritical fluid (SFC) conditions.
[0204] Normal phase flash chromatography: Unless otherwise stated, normal phase flash column chromatography (FCC) was performed on silica gel using prepacked silica gel columns using ethyl acetate (EtOAc) / hexane, ethyl acetate (EtOAc) / petroleum ether (bp 60°C to 90°C), CH2Cl2 / MeOH, or CH2Cl2 / 10% 2N NH3 in MeOH as eluents.
[0205] 1 H NMR: Unless otherwise stated, 1 H NMR spectra were obtained using a 400 MHz spectrometer (or a 300 MHz spectrometer) in DMSO-d6 solution. Nuclear magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ) expressed in parts per million (ppm). Tetramethylsilane (TMS) was used as an internal standard in DMSO-d6 solution, and the residual CH3OH peak or TMS was used as an internal standard in CD3OD solution. Coupling constants (J) were reported in Hertz (Hz). The properties of the shifts with respect to multiplicity were reported as s (singlet), d (doublet), t (triplet), q (quartet), dd (double of doublets), dt (double of triplets), m (multiplet), br (broad peak).
[0206] The abbreviations used in this specification, particularly in the examples, are listed in the table below:
[0207] Example 1. Synthesis of Compound Y
[0208] Step 1. Synthesis of 2-(Benzo[d][1,3]dioxolane-5-yl)ethan-1-ol
[0209] To a solution of 1,3-benzodioxole-5-acetic acid (500 g, 2.78 mol) in THF (200 mL) was added LAH (2.5 M, 1.00 L) dropwise at 0°C, and the mixture was stirred at 25°C under a N2 atmosphere for 12 hours. The mixture was cooled to -10 to 0°C, and then H2O (95.0 mL), NaOH (15%, 95.0 mL), and H2O (285 mL) were added in that order. After 0.5 hours, Na2SO4 (500 g) was added to the mixture, and the mixture was stirred at 25°C for 0.5 hours. The mixture was filtered, and the filter cake was washed with THF (5.00 L). The filtrate was collected and concentrated. The title compound (460 g, 2.77 mol, 99.7% yield) was obtained as a yellow oil.
[0210] Step 2. Synthesis of 2-(Benzo[d][1,3]dioxolan-5-yl)ethane-1-pivalate
[0211] 2-(Benzo[d][1,3]dioxolane-5-yl)ethane-1-ol (455 g) and pyridine (435 g) were dissolved in DCM (2.00 L), compound b (664 g) was added dropwise at 0 ° C. under N2 protection, and stirring was continued for 8 hours. The residue was poured into water, and the aqueous phase was extracted with DCM. The combined organic phase was washed with brine, dried, and concentrated. The residue was purified by silica gel chromatography to obtain the title compound (670 g) as a yellow oil.
[0212] HNMR (CDCl3): δ 6.78-6.70 (m, 2H), 6.68-6.64 (m, 1H), 6..10-5.58 (m, 2H), 4.22 (t, J = 6.94Hz, 2H), 2.84 (t, J = 6.94Hz, 2H), 1.20-1.16 (m, 9H).
[0213] Step 3. Synthesis of 2-(6-acetyl-benzo[d][1,3]dioxolan-5-yl)ethane-1-pivalate
[0214] To a solution of 2-(benzo[d][1,3]dioxolane-5-yl)ethane-1-pivalate (620 g) in AcO (3.00 L) at 0°C, ZnCl (1.01 kg) was added in one portion under N, and the mixture was stirred at room temperature for another 8 hours. The reaction was poured into water and extracted with ethyl acetate, and the combined organic phases were washed with brine, dried, and concentrated. Purification by silica gel chromatography afforded the title compound (467 g) as a yellow oil.
[0215] HNMR(CDCl3): δ7.23(s,1H),6.75(s,1H),6.78-6.70(m,1H),6.02(s,2H),4.26(t,J= 6.63Hz, 1H), 4.35-4.21 (m, 1H), 3.17 (t, J = 6.63Hz, 2H), 2.54 (s, 3H), 1.16 (s, 9H).
[0216] Step 4. Synthesis of ethyl 2-(6-(2-(2-(1,3-dioxolan-2-yl)-4,5-dimethoxyphenyl)acetyl)benzo[d][1,3]dioxolan-5-yl)pivalate
[0217] CsCO (451 g) and (Ahphos)PdCl (58.8 g) were added to a DCE solution of 2-(6-acetyl-benzo[d][1,3]dioxolane-5-yl)ethane-1-pivalate (284 g) and compound a (200 g) at room temperature under N protection. The mixture was reacted at 90°C for 10 hours. After the reaction, the reaction system was slowly added dropwise to water and extracted with ethyl acetate. The organic phase was washed with brine, dried, and concentrated. Purification by silica gel chromatography afforded the title compound (310 g) as a yellow solid.
[0218] Step 5. Synthesis of Compound Y
[0219] Under N2 protection at room temperature, to a solution of ethyl 2-(6-(2-(2-(1,3-dioxolane-2-yl)-4,5-dimethoxyphenyl)acetyl)benzo[d][1,3]dioxolane-5-yl)pivalate (310 g) in EtOH was added a single NH4Cl solution (3 M, 3.38 eq), and the mixture was reacted at 120°C under high pressure for 24 hours. After the reaction, the mixture was cooled to 25°C, filtered, and the filter cake was washed with MTBE. Purification by silica gel chromatography gave 190 g of the title compound.
[0220] HNMR(DMSO-d6): δ9.73-9.41(s,1H),8.91-8.58(s,1H),7..79-7.66(s,2H),7.62-7.55(s,1H),7.15-7.0 4(s,1H),6.23-6.09(s,2H),4.86-4.69(m,2H),4.10-4.04(m,3H),4.02-3.97(s,3H),3.25-3.15(m,2H).
[0221] Example 2. Synthesis of Compound N
[0222] Step 1. Synthesis of 3α,7β-diformyloxy-5β-cholestane-24-oic acid
[0223] Deoxycholic acid (500 g) was dissolved in formic acid (2.50 L) at room temperature and then stirred at 55° C. under a N atmosphere for 4 hours. After the reaction was complete, the reaction mixture was concentrated under vacuum to obtain the title compound as a crude product, which was used directly in the next reaction.
[0224] Step 2. Synthesis of 3α,7β-diformyloxy-5β-23-cyano-cholestane
[0225] To a solution of TFAA (trifluoroacetic anhydride) (927 g) in TFA (2.00 L) was added 3α, 7β-diformyloxy-5β-cholestane-24-acid (660 g), NaNO2 (112 g) at 0 ° C and the mixture was stirred for 1 hour, then heated to 40 ° C and continued stirring for 8 hours. The mixture was then cooled to 25 ° C, poured into water (6.00 L) and stirred for 30 minutes. It was extracted with ethyl acetate, the combined organic phases were washed with brine, dried and concentrated. Purified by silica gel chromatography to obtain the title compound (550 g) as a yellow solid, which was directly used in the next step reaction as a crude product.
[0226] Step 3. Synthesis of Compound N
[0227] To a solution of 3α,7β-diformyloxy-5β-23-cyano-cholestane (300g) dissolved in EtOH (2.80L), 40% KOH aqueous solution (2.80L) was added, and the mixture was then stirred at 110°C in an autoclave for 8 hours. After the reaction was complete, the mixture was cooled to 25°C and poured into water (4.00L). The aqueous phase was extracted with ethyl acetate, the aqueous phase was adjusted to pH=2, the aqueous phase was extracted with ethyl acetate, dried, and concentrated. Purified by silica gel chromatography to obtain the title compound (130g) as a yellow solid.
[0228] HNMR(MeOD): δ3.56-3.42(m,2H),2.44(d,J=11.52Hz,1H),2.08-1.78(m,7H),1.68-1 .4(m,9H),1.40-1.06(m,7H),1.02(d,J=6.14Hz,3H),0.97(s,3H),0.78-0.72(m,3H).
[0229] Example 3. Preparation and characterization of YN salt
[0230] Preparation of the YN salt: Prepare supersaturated solutions of compound Y and compound N in water. Add the saturated Y solution dropwise to the supersaturated N solution in water and continue stirring for 24 hours to produce a large amount of solid. Filter the resulting solid and dry it to obtain the solid salt form.
[0231] Characterization of YN salt: The melting point of the YN salt is 224-226°C. The ion ratio of Y and N in the YN salt is 1:1. HNMR (DMSO-d6): δ11.96 (s, 1H), 9.59 (s, 1H), 9.78 (s, 1H), 7.73 (s, 2H), 7.59 (s, 1H), 7.10 (s, 1H), 6.18 (s, 2H), 4.80-4.77 (t, 2H), 4.46-4.45 (d, 1H), 4.07 (s, 3H), 4.00 (s, 3H), 3.89-3.88 (d, 2H), 3.32-3.25 (m, 2H), 3. 21~3.18(t,2H),2.32~2.28(dd,1H),1.94~1.91(d,,1H),1.87~1.81(m,2H),1.77~1.67(m,3H),1.65~1.62(m ,1H),1.50~1.43(m,3H),1.42~1.26(m,6H),1.23~1.01(m,6H),0.95~0.91(dd,4H),0.87(s,3H),0.64(s,3H).
[0232] Example 4. Effects of Compound Y alone, Compound B alone, and Compound N alone on protecting hepatocytes from deoxycholic acid-induced hepatocyte injury
[0233] First, 2.5*10 4HepG2 cells were seeded in 96-well flat-bottom plates using MEM medium supplemented with 10% fetal bovine serum. They were cultured overnight in a 37°C, 5% CO2 incubator for adhesion, and then incubated with various compounds at corresponding concentrations (Compound Y 100 μM, Compound B 100 μM, and Compound N 50 μM) for 24 hours in a 37°C, 5% CO2 incubator. Except for the blank control group, all groups were treated with 1 mM deoxycholic acid (DCA, a secondary bile acid that can directly induce hepatocyte damage) for 4 hours. All groups were added with 10 μL of CCK8 reagent and incubated in a humidified incubator for 1 hour. The absorbance was measured at a wavelength of 450 nm using a microplate reader, which indirectly reflects the number of viable cells. All data are presented as a percentage of the absorbance measured in the blank control group, which was not treated with deoxycholic acid.
[0234] As shown in Figure 1, compared with the deoxycholic acid-treated group in Group 2 (column 2), the cell viability of Compound B (column 3) and Compound Y (column 4) was significantly improved, the cell viability of Compound N (column 5) showed an increasing trend but not significantly, and the effect of Compound Y (column 4) in improving cell viability was significantly better than that of Compound B (column 3).
[0235] The above results indicate that the hepatocellular protective effect of compound Y alone is significantly superior to that of compound B alone and compound N alone against deoxycholic acid-induced hepatocellular injury.
[0236] Example 5. Effects of Compound Y alone, Compound N alone, Compound Y+N (1:1) and YN salt on protecting hepatocytes from deoxycholic acid-induced hepatocyte injury
[0237] First, 2.5*10 4 HepG2 cells were seeded in 96-well flat-bottom plates using MEM medium supplemented with 10% fetal bovine serum. They were cultured overnight in a 37°C, 5% CO2 incubator to allow for adhesion. Subsequently, various compounds (50 μM compound Y, 50 μM compound N, 50 μM compound combination Y+N+50 μM (1:1 molar ratio), and 50 μM YN salt) were incubated with the HepG2 cells at the appropriate concentrations for 24 hours in a 37°C, 5% CO2 incubator. Except for the blank control group, all groups were treated with 1 mM deoxycholic acid (DCA), a secondary bile acid that can directly induce hepatocellular damage, for 4 hours. All groups were then treated with 10 μL of CCK8 reagent and incubated in a humidified incubator for 1 hour. Absorbance, an indirect indicator of viable cell count, was measured at 450 nm using a microplate reader. All data are presented as a percentage of the absorbance measured in the blank control group, which was not treated with DCA.
[0238] As shown in Figure 2, compared to the deoxycholic acid-treated group in Group 2 (column 2), compound Y (column 3) significantly increased cell viability to 72%. Compound N (column 4) showed a trend toward improvement, but not significant. YN salt (column 6) and compound combination Y + N (column 5) significantly increased cell viability to approximately 80%, demonstrating that compound Y, compound combination Y + N, and YN salt have significant protective effects against DCA-induced hepatocellular injury. Compound combination Y + N (column 5) and YN salt (column 6) exhibited comparable effects on increasing cell viability. Compared to compound Y alone in Group 3 (column 3) and compound N alone in Group 4 (column 4), YN salt (column 6) was superior in reducing deoxycholic acid-induced hepatocellular injury.
[0239] The above results indicate that YN salt and compound combination Y+N have significantly better hepatocellular protective effects than single compound Y or single compound N against deoxycholic acid-induced hepatocellular damage.
[0240] Example 6. Effects of Compound Y alone, Compound N alone, and Compound Y+N (2:1) combination on protecting hepatocytes from deoxycholic acid-induced hepatocyte injury
[0241] First, 2.5*10 4 HepG2 cells were seeded in 96-well flat-bottom plates using MEM medium supplemented with 10% fetal bovine serum. They were cultured overnight in a 37°C, 5% CO2 incubator to allow for adhesion. Subsequently, various compounds were incubated with the cells at the corresponding concentrations (Compound Y 100 μM, Compound N 50 μM, and Compound Y + N combination 100 μM + 50 μM (2:1 molar ratio)) at 37°C, 5% CO2 for 24 hours. All groups, except the blank control, were treated with 1 mM deoxycholic acid (DCA), a secondary bile acid that can directly induce hepatocellular damage, for 4 hours. All groups were treated with 10 μL of CCK8 reagent and incubated in a humidified incubator for 1 hour. Absorbance was measured at 450 nm using a microplate reader, indirectly reflecting the number of viable cells. All data are presented as a percentage of the absorbance measured in the blank control group, which was not treated with DCA.
[0242] As shown in Figure 3, compared with the deoxycholic acid-treated group in group 2 (column 2), the cell viability of compound Y (column 3) and compound combination Y+N (column 5) increased to more than 80%, which was a very significant difference, indicating that they have a significant protective effect on DCA-induced hepatocyte damage.
[0243] Example 7. Effects of Compound Combination Y+N (2:1) and Compound B+N (2:1) on Protecting Hepatocytes from Deoxycholic Acid-Induced Hepatocyte Injury
[0244] First, 2.5*10 4 HepG2 cells were seeded in 96-well flat-bottom plates using MEM medium supplemented with 10% fetal bovine serum. They were cultured overnight in a 37°C, 5% CO2 incubator to allow for adhesion. Subsequently, various compounds (compound combination Y + N 100 μM + 50 μM (2:1 molar ratio), compound combination B + N 100 μM + 50 μM (2:1 molar ratio)) were incubated with the HepG2 cells at the corresponding concentrations for 24 hours in a 37°C, 5% CO2 incubator. Except for the blank control group, all groups were treated with 1 mM deoxycholic acid (DCA), a secondary bile acid that can directly induce hepatocellular damage, for 4 hours. All groups were treated with 10 μL of CCK8 reagent and incubated in a humidified incubator for 1 hour. Absorbance was measured at 450 nm using a microplate reader, indirectly reflecting the number of viable cells. All data are presented as a percentage of the absorbance measured in the blank control group, which was not treated with DCA.
[0245] As shown in Figure 4, compared with the deoxycholic acid-treated group in group 2 (column 2), the third group of compound combination B+N had a tendency to increase cell viability but the effect was not significant, while the fourth group of compound combination Y+N had a very significant increase in cell viability; and the effect of compound combination Y+N in increasing cell viability was significantly better than that of compound combination B+N.
[0246] The above results show that compound combination Y+N has excellent hepatocellular protective effect against deoxycholic acid-induced hepatocellular damage and is significantly better than compound combination B+N.
[0247] Example 8. Effects of Compound Y alone, Compound N alone, and Compound Y+N combination on the proliferation of CD4-positive and CD8-positive T cells
[0248] It is reported that CD4 + T cells and CD8 +Overactive proliferation of T cells is involved in the pathogenesis of liver diseases such as primary sclerosing cholangitis and primary biliary cirrhosis (Tanja Schoknecht et al., CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood, J Leukoc Biol. 2017 Feb; 101(2): 589-597. doi: 10.1189 / jlb.5A1015-469R. Epub 2016 Sep 14.; Aliya F Gulamhusein et al., Primary biliary cholangitis: pathogenesis and therapeutic opportunities, Nat Rev Gastroenterol Hepatol. 2020 Feb; 17(2): 93-110.). In order to observe the inhibition of immune cell infiltration or proliferation by the compounds, compound combinations or salts of the present invention, their effects on inhibiting the proliferation of CD4-positive and CD8-positive T cells were further analyzed.
[0249] First, a certain number of human peripheral blood mononuclear cells (PBMCs) were incubated with 5 μM CellTrace cell proliferation detection reagent in a 37°C, 5% CO2 incubator in the dark for 20 minutes. 5CellTrace-stained PBMCs were seeded into 96-well U-bottom plates and treated with Anti-CD3 / CD28 antibody-coupled magnetic beads at a ratio of 1:1 (number of cells: number of magnetic beads) to stimulate PBMC differentiation into T cells. Various compounds were then incubated with the treated cells at corresponding concentrations (Compound Y 200 μM, Compound N 100 μM, Compound combination Y+N 200+100 μM, control group UDCA (100 μM)) at 37°C and 5% CO2 in an incubator for 72 hours, and then analyzed by flow cytometry. Specifically, the cells to be tested were first treated with Live / dead dye (633 nm, 1:1000 dilution) at 4°C for 30 minutes to distinguish dead cells from live cells. Subsequently, at room temperature, the above-mentioned cells to be tested were incubated with wavelength dyes anti-CD45-PerCPCy5.5, anti-CD4-AF700, and anti-CD8-FITC for 30 minutes to distinguish different series of T cells (CD4 positive T cells, CD8 positive T cells). After appropriate washing, the above-mentioned stained cells were analyzed by flow cytometry at different wavelengths. Subsequent cell analysis refers to live cells that appear positive after staining with Live / dead dyes. CD4-positive T cells refer to positive cells stained with anti-CD45-PerCPCy5.5 and anti-CD4-AF700 dyes; CD8-positive T cells refer to positive cells stained with anti-CD45-PerCPCy5.5 and anti-CD8-FITC dyes. The proliferation of CD4-positive and CD8-positive T cells is determined by the fluorescence of Celltrace dyes.
[0250] As shown in Figure 5, compared with the DMSO control group (waveform 1, waveforms 1-5 from top to bottom), the CD4-positive T cell proliferation peaks of the corresponding doses of compound Y (waveform 2) and compound combination Y+N (waveform 4) shifted to the right as a whole, indicating that the above groups significantly inhibited the proliferation of CD4-positive T cells. Similarly, as shown in Figure 6, compared with the DMSO control group (waveform 1), the CD8-positive T cell proliferation peaks of compound Y (waveform 2) and compound combination Y+N (waveform 4) shifted to the right as a whole, indicating that the above groups significantly inhibited the proliferation of CD8-positive T cells.
[0251] The above results show that compound Y and compound combination Y+N have significantly inhibited the proliferation of CD4-positive and CD8-positive T cells derived from human PBMC induced by Anti-CD3 / CD28, and their effects are significantly better than compound N and compound U (UDCA); indicating that compound Y and compound combination Y+N have the potential to inhibit liver and bile duct inflammation.
[0252] Example 9. Effects of Compound Y and Compound B on serological parameters of mice orally administered with α-naphthyl isothiocyanate (ANIT).
[0253] To validate the technical efficacy demonstrated in the in vitro cell model, this study further examined the effects of various compounds Y and B on serological parameters in a mouse model treated with α-naphthyl isothiocyanate (ANIT) via gavage. Fifty-four 6-8 week old female C57BL / 6 mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. After one week of acclimation, the mice were divided into six groups based on body weight, with this time point designated as Day -3. Each group received the test compound via gavage starting on Day -3 and continuing for three days. The model was then established by gavage at a dose of 50 mg / kg ANIT, designated Day 0. The healthy control group (control) received a single oral dose of pure olive oil. Throughout the experiment, both the healthy control group and the model (ANIT) group received the appropriate body weight-based dose of vehicle (sodium carboxymethylcellulose). The health and weight of the mice were observed daily. The experimental endpoint was Day 2; mice were fasted for 6 hours before euthanasia, and cardiac blood and liver samples were obtained under anesthesia. The primary indicators are serological changes including AST, ALT, and ALP. The specific groups and dosages for each group are as follows:
[0254] As shown in Figure 7, compared with the model group (ANIT, Group 2), the high-dose Compound Y group (100 mg / kg, Group 3) significantly reduced serum alkaline phosphatase (ALP) levels. The low-dose Compound Y group (50 mg / kg, Group 4) also reduced serum alkaline phosphatase (ALP) levels, while Compound B dose-dependently increased serum ALP levels, indicating that Compound Y was significantly more effective than Compound B in reducing serum ALP levels. As shown in Figure 8, compared with the model group (ANIT, Group 2), the high-dose Compound Y group (100 mg / kg, Group 3) significantly reduced serum ALT levels. The low-dose Compound Y group (50 mg / kg, Group 4) also reduced serum ALT levels, while Compound B dose-dependently increased serum ALT levels, indicating that Compound Y was significantly more effective than Compound B in reducing serum ALT levels. As shown in Figure 9, compared with the model group (ANIT, Group 2), the Compound Y group dose-dependently reduced serum AST levels, while Compound B dose-dependently increased serum AST levels, indicating that Compound Y was significantly more effective than Compound B in reducing serum AST levels.
[0255] The above results show that compound Y significantly reduces serum ALP and serum ALT levels, reduces serum AST levels, can reduce ANIT-induced cholestasis and bile duct epithelial cell damage, and can protect the liver from cholestasis-induced damage. Its effect is significantly better than compound B.
[0256] Example 10. Effects of various compound combinations on serological parameters of mice orally administered with α-naphthyl isothiocyanate (ANIT).
[0257] To validate the technical efficacy demonstrated in the DDC model, this study further examined the effects of various compound combinations on serological parameters in mice gavaged with α-naphthyl isothiocyanate (ANIT). Fifty-six female C57BL / 6 mice, 6-8 weeks old, were purchased from Shanghai Lingchang Biotechnology Co., Ltd. After one week of acclimation, the mice were divided into seven groups based on body weight, with this time point designated as Day -3. Each group received the compound by gavage starting on Day -3 and continuing for three days. The model was then established by gavage with ANIT at a dose of 50 mg / kg, designated Day 0. A normal control group received a single oral dose of pure olive oil. Throughout the experiment, both the healthy (control) and model (ANIT) groups received the appropriate dose of vehicle (sodium carboxymethylcellulose) based on body weight. The health and weight of the mice were observed daily. The experimental endpoint was Day 2; mice were fasted for 6 hours before euthanasia, and cardiac blood and liver samples were obtained under anesthesia. Serological changes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alanine aminotransferase (ALP), were the primary endpoints. The specific groups and dosages of each group are as follows:
[0258] As shown in Figure 10, compared with the model group (ANIT group, group 2), the positive control group (UDCA, group 3) reduced serum alkaline phosphatase (ALP) levels. Compound combinations Y+N (group 6) and Y+U (group 7) both significantly reduced serum alkaline phosphatase (ALP) levels by approximately 2-fold, significantly alleviating primary sclerosing cholangitis. Compound combination Y+N (group 6) was significantly more effective than compound combination B+N (group 5). As shown in Figure 11, compared with the model group (ANIT group, group 2), the positive control group (UDCA, group 3) significantly increased serum ALT levels, while compound combination Y+N (group 6) significantly reduced serum ALT levels, indicating that compound combination Y+N has a significant hepatoprotective effect. As shown in Figure 12, compared with the model group (ANIT group, group 2), the positive control group (UDCA, group 3) significantly increased serum AST levels, while compound combination Y+N (group 6) significantly reduced serum AST levels, indicating that compound combination Y+N has a significant hepatoprotective effect.
[0259] These results demonstrate that compound combination Y + N significantly reduced serum ALP levels, reduced ANIT-induced cholestasis, and reduced bile duct epithelial cell damage, with significantly superior effects compared to compound combination B + N. Furthermore, compound combination Y + N significantly reduced serum ALT and AST levels, protecting the liver from cholestasis-induced damage, with significantly superior effects compared to the positive control group U.
[0260] Example 11. Effects of Compound Y alone (Y), Compound N alone (N), Compound combination Y+N, and the positive control UDCA (U) on serological parameters in mice fed a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model).
[0261] 71 10-week-old male C57BL / 6 mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. After one week of adaptive feeding of the mice, the healthy control group was fed with normal feed, and the other groups were fed with feed containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrotrimethylpyridine (DDC), and this time point was recorded as day 0. Each group of compounds was gavage-administered starting on day 0. During the entire experiment, the healthy group (control) and the model group (DDC) were given the corresponding dose of solvent (sodium carboxymethyl cellulose) according to body weight. The health status and weight changes of the mice were observed every day. The end point of the experiment was day 20. The mice were fasted for 6 hours before euthanasia, and blood and liver samples were obtained under anesthesia. The primary indicators were serological changes including AST, ALT, and ALP; pathological analysis was performed by HE staining. The specific grouping and dosage of each group are shown in the following table:
[0262] As shown in Figure 13 , compared to the model group (DDC group) (Group 2), all experimental groups except the low-dose Compound Y (60 mg / kg) significantly reduced serum alkaline phosphatase (ALP) levels. Compared to the model group (DDC group) (Group 2) and the positive control group (Group 3), the compound combination Y + N experimental groups (Groups 6 and 9) showed dose-dependent reductions in serum ALP levels. Compared to 100 mg / kg Compound Y (Group 4) and 56.5 mg / kg Compound N (Group 5), the high-dose Compound Y + N combination (Group 6) significantly reduced serum ALP levels.
[0263] The above results showed that compared with compound Y and compound N, compound combination Y+N significantly reduced serum ALP levels.
[0264] Example 12. Effects of various compound combinations on serological parameters of mice fed with a diet containing 0.1% diethyl-1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC model).
[0265] Fifty-six 10-week-old male C57BL / 6 mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. After one week of adaptive feeding of the mice, the healthy control group was fed with normal feed, and the other groups were fed with feed containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrotrimethylpyridine (DDC), and this time point was recorded as day 0. Each group of compounds was gavage-administered starting on day 0. During the entire experiment, the healthy group (control) and the model group (DDC) were given the corresponding dose of solvent (sodium carboxymethyl cellulose) according to body weight. The health status and weight changes of the mice were observed every day. The end point of the experiment was day 20. The mice were fasted for 6 hours before euthanasia, and blood and liver samples were obtained under anesthesia. The primary indicators were serological changes including AST, ALT, and ALP; pathological analysis was performed by HE staining. The specific grouping, dosage and administration time of each group are as follows:
[0266] As shown in Figure 14, compared with the model group DDC group (Group 2), each group significantly reduced serum alkaline phosphatase (ALP) levels; wherein compared with the model group DDC group (Group 2), compound combination B + N (Group 5) and compound combination Y + N (Group 6) serum ALP levels decreased by more than 2 times. Compared with the positive control group UDCA (U, Group 3), compound combination B + N (Group 5) and compound combination Y + N (Group 6) more significantly reduced serum ALP levels. As shown in Figures 15 and 16, compared with the model group DDC group (Group 2), compound combination Y + N (Group 6) were able to significantly reduce serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, indicating that it has the effect of significantly reducing liver damage. As shown in Figure 17, compared with the model group DDC group (second group), the liver bile pigment-positive area of the positive control group U (third group), compound combination B+N (fifth group), compound combination Y+N (sixth group) and compound combination Y+U (seventh group) was significantly reduced, indicating that they significantly reduced the level of bile pigment in the liver. As shown in Figure 18, compared with the model group DDC group (second group), only compound combination Y+N (sixth group) significantly reduced the level of collagen in the liver, indicating that they significantly inhibited liver fibrosis, and the effect of compound combination Y+N (sixth group) was significantly better than that of compound combination B+N (fifth group).
[0267] These results demonstrate that compound combination Y+N lowers serum ALP levels, significantly outperforming the positive control group, UDCA. Compound combination Y+N also significantly reduces serum ALT and AST levels, demonstrating that compound combination Y+N mitigates liver damage caused by cholestasis. Furthermore, from a histopathological perspective, compound combination Y+N significantly reduces the area of bile pigment deposition and collagen in the liver, with significantly better results than compound combination B+N.
[0268] Example 13. Effects of compound combination Y+N on inflammatory bowel disease induced in mice fed with drinking water containing dextran sulfate sodium salt (DSS).
[0269] Cholestatic liver disease is often accompanied by inflammatory bowel disease. For example, more than 50% of patients with primary sclerosing cholangitis are accompanied by inflammatory bowel disease (Primary Sclerosing Cholangitis Diagnosis and Treatment Guidelines (2021)), and 80% of patients are accompanied by inflammatory bowel disease (Mago, S. and GYWu (2020). "Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review." J Clin Transl Hepatol 8(3): 336-346.). This experiment is to verify the regulatory effect of compound combination Y+N on inflammatory bowel disease. 30 6-8 week old female C57BL / 6 mice were purchased from Shanghai Lingchang Biotechnology Co., Ltd. After 1 week of adaptive feeding, the mice were divided into 3 groups according to body weight, and this time point was designated as day 0. In addition to the control group, mice in the model group and compound combination Y+N groups were given a 3% DSS solution for oral administration from Day 0 to Day 7. Compound combination Y+N groups were administered with the corresponding vehicle via gavage, with Day 8 being the endpoint. During the experiment, mice were observed daily for health, weight change, stool characteristics, and blood in stool. Mice were fasted for 6 hours before euthanasia, and colon samples were obtained under anesthesia.
[0270] As shown in Figure 19, compared with the control group, the model group (DSS) began to experience significant weight loss on the fourth day and continued until the end of the experiment; compared with the model group (DSS), the compound combination Y+N group significantly increased the weight of mice starting from the fourth day, indicating that the compound combination Y+N can significantly improve the survival status of mice with inflammatory bowel disease. The DAI score is a comprehensive assessment model for evaluating inflammatory bowel disease based on body weight, stool characteristics, and blood in stool. As shown in Figure 20, starting from the third day of DSS drinking, the DAI score of mice in the DSS group was significantly higher than that of the control group. As the drinking time extended, the DAI score of mice in the DSS model group reached 9 points; while the DAI score of mice in the compound combination Y+N group was significantly lower than that of the DSS model group starting from the fourth day, indicating that the compound combination Y+N can significantly improve the comprehensive symptoms of inflammatory bowel disease in mice. Inflammatory bowel disease can cause colon shortening. As shown in Figure 21, the colon length of mice in the model (DSS) group was shortened by approximately 30%, while the compound combination Y + N group was able to significantly maintain the length of the mouse colon, indicating that the compound combination Y + N can significantly improve the symptoms of colon shortening in mice with inflammatory bowel disease. In summary, the compound combination Y + N significantly improved DSS-induced ulcerative colitis in mice.
[0271] It should be understood that after reading the above content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A combination product comprising: (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof: Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl; or R 1 , R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; or R 4 , R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; (b) bile acid or a derivative or analogue thereof, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
2. The combination product according to claim 1, wherein R 1 , R 2 and R 3 are each independently selected from: hydrogen, hydroxy, methoxy and benzyloxy, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
3. A combination product according to claim 1 or 2, wherein R 4 , R 5 and R 6 are independently selected from: hydrogen, hydroxyl and methoxy, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
4. A combination product according to any one of the preceding claims, wherein R 1 , R 2 and R 3 One or both of them are hydrogen, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
5. A combination product according to any one of the preceding claims, wherein R 4 , R 5 and R 6 One or both of them are hydrogen, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
6. A combination product according to any one of the preceding claims, wherein the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate; preferably maleate or hydrochloride, more preferably hydrochloride.
7. A combination product according to any one of the preceding claims, wherein the compound of formula (I) is selected from:
8. A combination product according to any one of the preceding claims, wherein the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-norursodeoxycholic acid and tauroursodeoxycholic acid.
9. A combination product according to any one of the preceding claims, wherein the molar ratio of component (a) to component (b) is 1:1000-1000:1; preferably, the molar ratio of component (a) to component (b) is 1:5-5:1; more preferably, the molar ratio of component (a) to component (b) is 1:2-2:1; further preferably, the molar ratio of component (a) to component (b) is 1:1-2:1; more preferably, the molar ratio of component (a) to component (b) is 1:1 or 2:
1.
10. A combination product according to any one of the preceding claims for use in the treatment and / or prevention of liver diseases, preferably chronic cholestatic liver diseases.
11. A combination product according to any one of the preceding claims, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer.
12. The combination product according to any one of the preceding claims, wherein the component (a) and component (b) have a synergistic effect in alleviating deoxycholic acid-induced hepatocellular injury.
13. A pharmaceutical composition comprising: (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof: Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl and phenyl; or R 1 , R 2 and R 3 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; or R 4 , R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; (b) bile acid or its derivative or analogue or its pharmaceutically acceptable salt, solvate, hydrate or stereoisomer; (c) pharmaceutically acceptable carriers, excipients and / or diluents.
14. The pharmaceutical composition according to claim 13, wherein R 1 , R 2 and R 3 are each independently selected from: hydrogen, hydroxy, methoxy and benzyloxy, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
15. The pharmaceutical composition according to claim 13 or 14, wherein R 4 , R 5 and R 6 are independently selected from: hydrogen, hydroxyl and methoxy, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
16. The pharmaceutical composition according to any one of claims 13 to 15, wherein R 1 , R 2 and R 3 One or both of them are hydrogen, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
17. The pharmaceutical composition according to any one of claims 13 to 16, wherein R 4 , R 5 and R 6 One or both of them are hydrogen, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
18. A pharmaceutical composition according to any one of claims 13 to 17, wherein a pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate; preferably maleate or hydrochloride, more preferably hydrochloride.
19. A pharmaceutical composition according to any one of claims 13 to 18, wherein the compound of formula (I) is selected from:
20. The pharmaceutical composition according to any one of claims 13 to 19, wherein the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid and tauroursodeoxycholic acid.
21. A pharmaceutical composition according to any one of claims 13 to 20, wherein the molar ratio of component (a) to component (b) is 1:1000-1000:1; preferably, the molar ratio of component (a) to component (b) is 1:5-5:1; more preferably, the molar ratio of component (a) to component (b) is 1:2-2:1; further preferably, the molar ratio of component (a) to component (b) is 1:1-2:1; more preferably, the molar ratio of component (a) to component (b) is 1:1 or 2:
1.
22. The pharmaceutical composition according to any one of claims 13 to 21, for use in the treatment and / or prevention of liver disease or inflammatory bowel disease, preferably chronic cholestatic liver disease.
23. A pharmaceutical composition according to any one of claims 13 to 22, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer.
24. The pharmaceutical composition according to any one of claims 13 to 23, wherein the component (a) and the component (b) have a synergistic effect in alleviating deoxycholic acid-induced hepatocellular injury.
25. An acid-base addition salt of formula (II): (A + ) m (B - ) n (C - ) p (II) in, (a)A + is the cationic portion of the compound of formula (I); Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different and are each independently selected from: hydrogen, halogen, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted by one or more groups selected from the following groups: halogen, C1-C6 alkyl and phenyl, or R 1 , R 2 and R 3 Any two adjacent ones of the carbon atoms to which they are attached together form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N, or R 4 , R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; (b)B - is the anionic portion of a bile acid or a derivative or analog thereof; and (c)C - It is an acid anion; wherein m, n and p are each independently an integer selected from 1 to 6 such that the salt configuration achieves charge balance, and when m=n, p is 0.
26. The acid-base addition salt according to claim 25, wherein R 1 , R 2 and R 3 are each independently selected from: hydrogen, hydroxy, methoxy and benzyloxy, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
27. The acid-base addition salt according to claim 25 or 26, wherein R 4 , R 5 and R 6 are independently selected from: hydrogen, hydroxyl and methoxy, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
28. The acid-base addition salt according to any one of claims 25 to 27, wherein R 1 , R 2 and R 3 One or both of them are hydrogen, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
29. The acid-base addition salt according to any one of claims 25 to 28, wherein R 4 , R 5 and R 6 One or both of them are hydrogen, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
30. The acid-base addition salt according to any one of claims 25 to 29, wherein the cationic portion of the compound of formula (I) is selected from the group consisting of:
31. The acid-base addition salt according to any one of claims 25 to 30, wherein the component (b) is an anionic portion selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-norursodeoxycholic acid and tauroursodeoxycholic acid.
32. The acid-base addition salt according to any one of claims 25 to 31, wherein m is 1, n is 1 and p is 0, or m is 2, n is 1 and p is 1.
33. The acid-base addition salt according to any one of claims 25 to 32 for use in the treatment and / or prevention of liver diseases or inflammatory bowel diseases, preferably chronic cholestatic liver diseases.
34. The acid-base addition salt according to any one of claims 25 to 33, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer.
35. A pharmaceutical composition comprising a combination product according to any one of claims 1 to 12 or an acid-base addition salt according to any one of claims 25 to 34.
36. A method for treating and / or preventing liver disease or inflammatory bowel disease, comprising administering to a patient in need thereof a combination product, a pharmaceutical composition, an acid-base addition salt, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of claims 1 to 35.
37. A method according to embodiment 36, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (especially progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (especially hepatocellular carcinoma) and bile duct cancer.
37. A method for treating and / or preventing liver disease or inflammatory bowel disease, comprising: Scheme 1, administering to a patient in need thereof: (a) a therapeutically and / or prophylactically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof: Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different and are each independently selected from: hydrogen, halogen, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted by one or more groups selected from the following groups: halogen, C1-C6 alkyl and phenyl, or R 1 , R 2 and R 3 Any two adjacent ones of the carbon atoms to which they are attached together form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N, or R 4 , R 5 and R 6 Any two adjacent ones of the carbon atoms to which they are attached together form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; or Scheme 2, administering simultaneously, concurrently, separately or sequentially to a patient in need thereof: (a) a therapeutically and / or prophylactically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or the like Compounds or stereoisomers: Where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are the same or different and are each independently selected from: hydrogen, halogen, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy, wherein the hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy are optionally substituted by one or more groups selected from the following groups: halogen, C1-C6 alkyl and phenyl, or R 1 , R 2 and R 3 Any two adjacent ones of the carbon atoms to which they are attached together form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N, or R 4 , R 5 and R 6 Any two adjacent ones of the group together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; and (b) a therapeutically and / or preventively effective amount of bile acid or a derivative or analog thereof or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
38. The method of claim 37, wherein R 1 , R 2 and R 3 are each independently selected from: hydrogen, hydroxy, methoxy and benzyloxy, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
39. The method according to claim 37 or 38, wherein R 4 , R 5 and R 6 are independently selected from: hydrogen, hydroxyl and methoxy, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 4-7 membered heterocyclic ring containing one or more oxygen atoms.
40. The method according to any one of claims 37-39, wherein R 1 , R 2 and R 3 One or both of them are hydrogen, or R 1 , R 2 and R 3 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
41. The method according to any one of claims 37-40, wherein R 4 , R 5 and R 6 One or both of them are hydrogen, or R 4 , R 5 and R 6 Any two adjacent ones of the groups together with the carbon atoms to which they are attached form a 5-membered heterocyclic ring containing one or more oxygen atoms.
42. The method according to any one of claims 37-41, wherein the pharmaceutically acceptable salt of the compound of formula (I) is selected from maleate, hydrochloride, oxalate, tartrate, fumarate, citrate, malate, adipate, methanesulfonate, phosphate, acetate, mandelate or sulfate; preferably maleate or hydrochloride, more preferably hydrochloride.
43. The method according to any one of claims 37-42, wherein the compound of formula (I) is selected from:
44. The method according to any one of claims 37-43, wherein the bile acid or its derivative or analogue is selected from the group consisting of cholic acid, obeticholic acid, ursodeoxycholic acid, chenodeoxycholic acid, hyodeoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iodocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, 24-demethylursodeoxycholic acid and tauroursodeoxycholic acid.
45. The method according to any one of claims 37-44, wherein the molar ratio of component (a) to component (b) is 1:1000-1000:1; preferably, the molar ratio of component (a) to component (b) is 1::5-5:1; more preferably, the molar ratio of component (a) to component (b) is 1:2-2:1; further preferably, the molar ratio of component (a) to component (b) is 1:1-2:1; more preferably, the molar ratio of component (a) to component (b) is 1:1 or 2:
1.
46. The method according to any one of claims 37-45, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer.
47. A combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to any one of claims 1 to 35 for use in treating, alleviating and / or preventing liver disease or inflammatory bowel disease.
48. The combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to claim 47, wherein the liver disease is selected from cholestatic liver disease (chronic cholestatic liver disease), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis type 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-choledochal cholestasis. Preferably, the liver disease is primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC); more preferably, the primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC) is accompanied by complication inflammatory bowel disease.
49. The combination product, pharmaceutical composition, acid-base addition salt, or compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof according to claim 47, wherein the inflammatory bowel disease is a complication caused by primary sclerosing cholangitis (PSC) and / or primary biliary cirrhosis (PBC).
50. A kit comprising: A combination product, an acid-base addition salt, a pharmaceutical composition, or a compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, and instructions for use according to any one of claims 1 to 35, wherein the kit is used to treat and / or prevent liver disease or inflammatory bowel disease.
51. A kit according to claim 50, wherein the liver disease is selected from cholestatic liver disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), progressive familial intrahepatic cholestasis (particularly progressive familial intrahepatic cholestasis types 1, 2 and 3), cystic fibrosis, drug-induced cholestasis or non-cholestatic liver disease, chronic viral hepatitis (B, C, D), alcoholic or non-alcoholic steatohepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease or alpha-1-antitrypsin deficiency, liver cancer (particularly hepatocellular carcinoma) and bile duct cancer.
Citation Information
Patent Citations
Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
CN103298825A
Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
CN106692973A
Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
CN110179792A
Methods and compositions for treatment of inflammatory bowel disease
CN111295203A
Acid-base addition salt containing berberine, preparation method of acid-base addition salt and application of acid-base addition salt as medicaments
CN112851660A
